OncoMatch/Clinical Trials/NCT04314219
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
Is NCT04314219 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Cyclophosphamide 50mg and Methotrexate for acute lymphoblastic leukemia (all) in complete remission.
Treatment: Cyclophosphamide 50mg · Methotrexate — This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard of care GVHD prophylaxis regimen (methotrexate/calcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors for their efficacy as a new GVHD prophylaxis strategy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Disease stage
Required: Stage COMPLETE REMISSION
Excluded: Stage ACTIVE DISEASE
Lab requirements
Kidney function
estimated creatinine clearance greater than 50 ml/minute
Liver function
total bilirubin < 2x the upper limit of normal (unless elevated bilirubin is attributed to gilbert's syndrome) and alt/ast < 2.5x the upper normal limit
Cardiac function
ejection fraction at rest ≥ 50% by muga or tte
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify